BusinessStrongbridge Biopharma plc Completes Target Enrollment of 90 Patients in the Phase 3 SONICS Study Evaluating RECORLEV™ (levoketoconazole) in Endogenous Cushing’s SyndromeBy Nasdaq OMXJun 27, 2017, 11:30 AM UTC
BusinessStrongbridge Biopharma plc Provides Corporate and Financial UpdateBy Nasdaq OMXDec 23, 2016, 1:03 PM UTC
